Infection, New England Journal of Medicine, vol.372, issue.16, pp.1539-1587, 2015. ,
DOI : 10.1056/NEJMra1403772
Infection in the United States, New England Journal of Medicine, vol.372, issue.9, pp.825-859, 2015. ,
DOI : 10.1056/NEJMoa1408913
Burden of Clostridium difficile on the Healthcare System, Clinical Infectious Diseases, vol.55, issue.suppl 2, pp.88-92, 2012. ,
DOI : 10.1093/cid/cis335
Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals Antibiotic resistance threats in the United States, Infect Control Hosp Epidemiol, vol.32, 2011. ,
Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation, Proceedings of the National Academy of Sciences, vol.88, issue.10, pp.4554-61, 2011. ,
DOI : 10.1890/06-1736.1
In vivo influence of three B-lactam antibiotics on the intestinal microflora of man. A preliminary study in gnotobiotic mice, Prog Clin Biol Res, vol.181, pp.279-82, 1985. ,
Oral Administration of ?????Lactamase Preserves Colonization Resistance of Piperacillin???Treated Mice, The Journal of Infectious Diseases, vol.188, issue.10, pp.1605-1614, 2003. ,
DOI : 10.1086/379153
Orally administered targeted recombinant Beta-lactamase prevents ampicillininduced selective pressure on the gut microbiota: a novel approach to reducing antimicrobial resistance P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin, Antimicrob Agents Chemother Antimicrob Agents Chemother, vol.48, issue.53, pp.2455-62, 2004. ,
Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection, Anaerobe, vol.41, pp.58-67, 2016. ,
DOI : 10.1016/j.anaerobe.2016.05.015
SYN-004 (ribaxamase), an oral betalactamase designed to protect the gut microbiome from the deleterious effects of certain intravenously administered beta-lactam antibiotics, degrades ceftriaxone excreted into the intestine in Phase 2a clinical studies, Antimicrob Agents, pp.2197-2213, 2017. ,
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zincpectinate beads, Clin Infect Dis Eur J Pharm Sci, vol.41, issue.41, pp.281-289, 2005. ,
Oral DAV131, a Charcoal-Based Adsorbent, Inhibits Intestinal Colonization by ??-Lactam-Resistant Klebsiella pneumoniae in Cefotaxime-Treated Mice, Antimicrobial Agents and Chemotherapy, vol.57, issue.11, pp.5423-5428, 2013. ,
DOI : 10.1128/AAC.00039-13
Morphology of experimental antibiotic-associated enterocolitis in the hamster: a model for human pseudomembranous colitis and antibiotic-associated diarrhoea., Gut, vol.20, issue.6, pp.467-75, 1979. ,
DOI : 10.1136/gut.20.6.467
In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile., Antimicrobial Agents and Chemotherapy, vol.35, issue.6, pp.1108-1119, 1991. ,
DOI : 10.1128/AAC.35.6.1108
Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters, Infection and Immunity, vol.74, issue.11, pp.6339-6386, 2006. ,
DOI : 10.1128/IAI.00982-06
Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties, Alimentary Pharmacology and Therapeutics, vol.141, issue.1, pp.1525-1559, 2006. ,
DOI : 10.1093/infdis/141.1.92
Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones166-9. 22. FDA Avelox label. https://www.accessdata.fda.gov/drugsatfda_docs/label Guide for the Care and Use of Laboratory Animals Penetration of moxifloxacin into the human aqueous humour after oral administration, Anaerobe Br J Ophthalmol, vol.17, issue.89, pp.628-659, 2005. ,
GT160-246, a Toxin Binding Polymer for Treatment of Clostridium difficile Colitis, Antimicrobial Agents and Chemotherapy, vol.45, issue.8, pp.2340-2347, 2001. ,
DOI : 10.1128/AAC.45.8.2340-2347.2001
Single- and Multiple-dose Pharmacokinetics of Oral Moxifloxacin and Clarithromycin, and Concentrations in Serum, Saliva and Faeces, Scandinavian Journal of Infectious Diseases, vol.34, issue.12, pp.898-90310, 2002. ,
DOI : 10.1080/0036554021000026963